nodes	percent_of_prediction	percent_of_DWPC	metapath
Olanzapine—ALB—acquired immunodeficiency syndrome	0.193	1	CbGaD
Olanzapine—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0413	0.0647	CbGbCtD
Olanzapine—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0175	0.0274	CbGbCtD
Olanzapine—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0174	0.0272	CbGbCtD
Olanzapine—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0167	0.0261	CbGbCtD
Olanzapine—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0164	0.0257	CbGbCtD
Olanzapine—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0161	0.0253	CbGbCtD
Olanzapine—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0152	0.0237	CbGbCtD
Olanzapine—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0152	0.0237	CbGbCtD
Olanzapine—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0149	0.0233	CbGbCtD
Olanzapine—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0149	0.0233	CbGbCtD
Olanzapine—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0145	0.0228	CbGbCtD
Olanzapine—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0137	0.0215	CbGbCtD
Olanzapine—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0137	0.0214	CbGbCtD
Olanzapine—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0137	0.0214	CbGbCtD
Olanzapine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0133	0.0208	CbGbCtD
Olanzapine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0133	0.0208	CbGbCtD
Olanzapine—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0128	0.0201	CbGbCtD
Olanzapine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0125	0.0196	CbGbCtD
Olanzapine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0125	0.0196	CbGbCtD
Olanzapine—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0125	0.0195	CbGbCtD
Olanzapine—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0124	0.0193	CbGbCtD
Olanzapine—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0124	0.0193	CbGbCtD
Olanzapine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.012	0.0188	CbGbCtD
Olanzapine—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0115	0.018	CbGbCtD
Olanzapine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0113	0.0177	CbGbCtD
Olanzapine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0113	0.0177	CbGbCtD
Olanzapine—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0113	0.0176	CbGbCtD
Olanzapine—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0113	0.0176	CbGbCtD
Olanzapine—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0108	0.0169	CbGbCtD
Olanzapine—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0107	0.0167	CbGbCtD
Olanzapine—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0104	0.0163	CbGbCtD
Olanzapine—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0104	0.0162	CbGbCtD
Olanzapine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0104	0.0162	CbGbCtD
Olanzapine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0101	0.0157	CbGbCtD
Olanzapine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00975	0.0153	CbGbCtD
Olanzapine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00947	0.0148	CbGbCtD
Olanzapine—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00937	0.0147	CbGbCtD
Olanzapine—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00937	0.0147	CbGbCtD
Olanzapine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00909	0.0142	CbGbCtD
Olanzapine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00909	0.0142	CbGbCtD
Olanzapine—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00898	0.0141	CbGbCtD
Olanzapine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00871	0.0136	CbGbCtD
Olanzapine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00856	0.0134	CbGbCtD
Olanzapine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00856	0.0134	CbGbCtD
Olanzapine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00845	0.0132	CbGbCtD
Olanzapine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00795	0.0124	CbGbCtD
Olanzapine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00795	0.0124	CbGbCtD
Olanzapine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00719	0.0113	CbGbCtD
Olanzapine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00719	0.0113	CbGbCtD
Olanzapine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00674	0.0106	CbGbCtD
Olanzapine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0062	0.00971	CbGbCtD
Olanzapine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00602	0.00943	CbGbCtD
Olanzapine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00545	0.00853	CbGbCtD
Olanzapine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00545	0.00853	CbGbCtD
Olanzapine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00522	0.00817	CbGbCtD
Olanzapine—H1F0—semen—acquired immunodeficiency syndrome	0.00359	0.0433	CbGeAlD
Olanzapine—ORM1—saliva—acquired immunodeficiency syndrome	0.00257	0.0309	CbGeAlD
Olanzapine—DRD1—nerve—acquired immunodeficiency syndrome	0.00171	0.0206	CbGeAlD
Olanzapine—HTR3A—nerve—acquired immunodeficiency syndrome	0.00165	0.0199	CbGeAlD
Olanzapine—HTR5A—nervous system—acquired immunodeficiency syndrome	0.00154	0.0186	CbGeAlD
Olanzapine—HTR5A—central nervous system—acquired immunodeficiency syndrome	0.00149	0.0179	CbGeAlD
Olanzapine—HRH4—blood—acquired immunodeficiency syndrome	0.00139	0.0167	CbGeAlD
Olanzapine—HRH4—bone marrow—acquired immunodeficiency syndrome	0.00134	0.0162	CbGeAlD
Olanzapine—HTR5A—brain—acquired immunodeficiency syndrome	0.00118	0.0142	CbGeAlD
Olanzapine—HTR7—nerve—acquired immunodeficiency syndrome	0.00107	0.0129	CbGeAlD
Olanzapine—DRD2—nerve—acquired immunodeficiency syndrome	0.00101	0.0122	CbGeAlD
Olanzapine—HTR7—endothelium—acquired immunodeficiency syndrome	0.00091	0.011	CbGeAlD
Olanzapine—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.000845	0.0102	CbGeAlD
Olanzapine—HTR7—blood plasma—acquired immunodeficiency syndrome	0.000808	0.00973	CbGeAlD
Olanzapine—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000789	0.0095	CbGeAlD
Olanzapine—HRH2—skin of body—acquired immunodeficiency syndrome	0.000764	0.0092	CbGeAlD
Olanzapine—CHRM5—skin of body—acquired immunodeficiency syndrome	0.00073	0.00879	CbGeAlD
Olanzapine—H1F0—retina—acquired immunodeficiency syndrome	0.000717	0.00864	CbGeAlD
Olanzapine—HTR2A—nerve—acquired immunodeficiency syndrome	0.000666	0.00802	CbGeAlD
Olanzapine—DRD5—lymphoid tissue—acquired immunodeficiency syndrome	0.000659	0.00793	CbGeAlD
Olanzapine—HTR1E—nervous system—acquired immunodeficiency syndrome	0.000659	0.00793	CbGeAlD
Olanzapine—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000644	0.00776	CbGeAlD
Olanzapine—HTR1E—central nervous system—acquired immunodeficiency syndrome	0.000634	0.00764	CbGeAlD
Olanzapine—H1F0—skin of body—acquired immunodeficiency syndrome	0.000629	0.00758	CbGeAlD
Olanzapine—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000612	0.00737	CbGeAlD
Olanzapine—HRH2—digestive system—acquired immunodeficiency syndrome	0.000611	0.00736	CbGeAlD
Olanzapine—FMO3—vagina—acquired immunodeficiency syndrome	0.000606	0.0073	CbGeAlD
Olanzapine—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.000592	0.00714	CbGeAlD
Olanzapine—DRD4—brain—acquired immunodeficiency syndrome	0.000584	0.00703	CbGeAlD
Olanzapine—HRH2—blood—acquired immunodeficiency syndrome	0.000582	0.00701	CbGeAlD
Olanzapine—CHRM4—nervous system—acquired immunodeficiency syndrome	0.000578	0.00696	CbGeAlD
Olanzapine—FMO3—lung—acquired immunodeficiency syndrome	0.000573	0.00691	CbGeAlD
Olanzapine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.000567	0.00683	CbGeAlD
Olanzapine—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.000556	0.0067	CbGeAlD
Olanzapine—DRD3—nervous system—acquired immunodeficiency syndrome	0.000537	0.00647	CbGeAlD
Olanzapine—FMO3—nervous system—acquired immunodeficiency syndrome	0.000531	0.0064	CbGeAlD
Olanzapine—DRD3—central nervous system—acquired immunodeficiency syndrome	0.000517	0.00623	CbGeAlD
Olanzapine—HTR6—nervous system—acquired immunodeficiency syndrome	0.000517	0.00623	CbGeAlD
Olanzapine—FMO3—central nervous system—acquired immunodeficiency syndrome	0.000511	0.00616	CbGeAlD
Olanzapine—HRH2—lung—acquired immunodeficiency syndrome	0.00051	0.00615	CbGeAlD
Olanzapine—H1F0—lymphoid tissue—acquired immunodeficiency syndrome	0.00051	0.00614	CbGeAlD
Olanzapine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.000504	0.00607	CbGeAlD
Olanzapine—HTR1E—brain—acquired immunodeficiency syndrome	0.000503	0.00606	CbGeAlD
Olanzapine—H1F0—digestive system—acquired immunodeficiency syndrome	0.000503	0.00606	CbGeAlD
Olanzapine—DRD5—nervous system—acquired immunodeficiency syndrome	0.000503	0.00606	CbGeAlD
Olanzapine—HTR6—central nervous system—acquired immunodeficiency syndrome	0.000498	0.00599	CbGeAlD
Olanzapine—DRD5—central nervous system—acquired immunodeficiency syndrome	0.000484	0.00584	CbGeAlD
Olanzapine—HTR3A—digestive system—acquired immunodeficiency syndrome	0.00048	0.00578	CbGeAlD
Olanzapine—H1F0—blood—acquired immunodeficiency syndrome	0.00048	0.00578	CbGeAlD
Olanzapine—HRH2—nervous system—acquired immunodeficiency syndrome	0.000473	0.00569	CbGeAlD
Olanzapine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000466	0.00562	CbGeAlD
Olanzapine—H1F0—bone marrow—acquired immunodeficiency syndrome	0.000464	0.00559	CbGeAlD
Olanzapine—H1F0—spinal cord—acquired immunodeficiency syndrome	0.000462	0.00557	CbGeAlD
Olanzapine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000459	0.00553	CbGeAlD
Olanzapine—HTR3A—blood—acquired immunodeficiency syndrome	0.000457	0.00551	CbGeAlD
Olanzapine—HRH2—central nervous system—acquired immunodeficiency syndrome	0.000455	0.00548	CbGeAlD
Olanzapine—HTR2B—skin of body—acquired immunodeficiency syndrome	0.000454	0.00546	CbGeAlD
Olanzapine—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000451	0.00544	CbGeAlD
Olanzapine—H1F0—vagina—acquired immunodeficiency syndrome	0.000445	0.00536	CbGeAlD
Olanzapine—CHRM4—brain—acquired immunodeficiency syndrome	0.000441	0.00532	CbGeAlD
Olanzapine—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.000435	0.00524	CbGeAlD
Olanzapine—H1F0—lung—acquired immunodeficiency syndrome	0.00042	0.00506	CbGeAlD
Olanzapine—DRD2—retina—acquired immunodeficiency syndrome	0.000418	0.00504	CbGeAlD
Olanzapine—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.000412	0.00497	CbGeAlD
Olanzapine—DRD3—brain—acquired immunodeficiency syndrome	0.00041	0.00494	CbGeAlD
Olanzapine—ORM1—blood—acquired immunodeficiency syndrome	0.000409	0.00493	CbGeAlD
Olanzapine—FMO3—brain—acquired immunodeficiency syndrome	0.000406	0.00489	CbGeAlD
Olanzapine—HTR3A—lung—acquired immunodeficiency syndrome	0.000401	0.00483	CbGeAlD
Olanzapine—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.000397	0.00478	CbGeAlD
Olanzapine—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000396	0.00477	CbGeAlD
Olanzapine—HTR6—brain—acquired immunodeficiency syndrome	0.000395	0.00476	CbGeAlD
Olanzapine—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000394	0.00475	CbGeAlD
Olanzapine—FMO3—lymph node—acquired immunodeficiency syndrome	0.000392	0.00472	CbGeAlD
Olanzapine—H1F0—nervous system—acquired immunodeficiency syndrome	0.000389	0.00469	CbGeAlD
Olanzapine—DRD5—brain—acquired immunodeficiency syndrome	0.000385	0.00463	CbGeAlD
Olanzapine—DRD1—nervous system—acquired immunodeficiency syndrome	0.000384	0.00463	CbGeAlD
Olanzapine—H1F0—central nervous system—acquired immunodeficiency syndrome	0.000375	0.00452	CbGeAlD
Olanzapine—HTR3A—nervous system—acquired immunodeficiency syndrome	0.000371	0.00447	CbGeAlD
Olanzapine—DRD1—central nervous system—acquired immunodeficiency syndrome	0.00037	0.00446	CbGeAlD
Olanzapine—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.00037	0.00445	CbGeAlD
Olanzapine—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000363	0.00437	CbGeAlD
Olanzapine—HRH2—brain—acquired immunodeficiency syndrome	0.000361	0.00435	CbGeAlD
Olanzapine—ORM1—lung—acquired immunodeficiency syndrome	0.000359	0.00432	CbGeAlD
Olanzapine—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.000357	0.00431	CbGeAlD
Olanzapine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000354	0.00427	CbGeAlD
Olanzapine—HRH2—lymph node—acquired immunodeficiency syndrome	0.000349	0.0042	CbGeAlD
Olanzapine—HTR2B—blood—acquired immunodeficiency syndrome	0.000346	0.00416	CbGeAlD
Olanzapine—CHRM5—brain—acquired immunodeficiency syndrome	0.000345	0.00416	CbGeAlD
Olanzapine—ORM1—nervous system—acquired immunodeficiency syndrome	0.000332	0.004	CbGeAlD
Olanzapine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00033	0.00398	CbGeAlD
Olanzapine—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000326	0.00393	CbGeAlD
Olanzapine—HTR2B—vagina—acquired immunodeficiency syndrome	0.00032	0.00386	CbGeAlD
Olanzapine—ORM1—central nervous system—acquired immunodeficiency syndrome	0.00032	0.00385	CbGeAlD
Olanzapine—ADRA1B—brain—acquired immunodeficiency syndrome	0.000315	0.0038	CbGeAlD
Olanzapine—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000312	0.00375	CbGeAlD
Olanzapine—HTR7—digestive system—acquired immunodeficiency syndrome	0.000311	0.00374	CbGeAlD
Olanzapine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.00031	0.00373	CbGeAlD
Olanzapine—CHRM1—lung—acquired immunodeficiency syndrome	0.000305	0.00367	CbGeAlD
Olanzapine—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000303	0.00365	CbGeAlD
Olanzapine—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000303	0.00365	CbGeAlD
Olanzapine—HTR2B—lung—acquired immunodeficiency syndrome	0.000303	0.00365	CbGeAlD
Olanzapine—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000302	0.00363	CbGeAlD
Olanzapine—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.0003	0.00361	CbGeAlD
Olanzapine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000299	0.0036	CbGeAlD
Olanzapine—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000298	0.00359	CbGeAlD
Olanzapine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000298	0.00359	CbGeAlD
Olanzapine—H1F0—brain—acquired immunodeficiency syndrome	0.000298	0.00359	CbGeAlD
Olanzapine—HTR7—blood—acquired immunodeficiency syndrome	0.000296	0.00357	CbGeAlD
Olanzapine—DRD1—brain—acquired immunodeficiency syndrome	0.000294	0.00354	CbGeAlD
Olanzapine—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.00029	0.0035	CbGeAlD
Olanzapine—CYP2C19—blood—acquired immunodeficiency syndrome	0.000289	0.00348	CbGeAlD
Olanzapine—H1F0—lymph node—acquired immunodeficiency syndrome	0.000288	0.00346	CbGeAlD
Olanzapine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000288	0.00346	CbGeAlD
Olanzapine—ADRA1A—blood—acquired immunodeficiency syndrome	0.000285	0.00344	CbGeAlD
Olanzapine—HTR7—spinal cord—acquired immunodeficiency syndrome	0.000285	0.00343	CbGeAlD
Olanzapine—HTR3A—brain—acquired immunodeficiency syndrome	0.000284	0.00342	CbGeAlD
Olanzapine—CHRM1—nervous system—acquired immunodeficiency syndrome	0.000282	0.0034	CbGeAlD
Olanzapine—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000281	0.00338	CbGeAlD
Olanzapine—HTR2A—retina—acquired immunodeficiency syndrome	0.000276	0.00332	CbGeAlD
Olanzapine—ADRA2C—blood—acquired immunodeficiency syndrome	0.000272	0.00328	CbGeAlD
Olanzapine—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000272	0.00327	CbGeAlD
Olanzapine—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.00027	0.00325	CbGeAlD
Olanzapine—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000268	0.00323	CbGeAlD
Olanzapine—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000262	0.00316	CbGeAlD
Olanzapine—HTR7—lung—acquired immunodeficiency syndrome	0.000259	0.00313	CbGeAlD
Olanzapine—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000252	0.00304	CbGeAlD
Olanzapine—ADRA2C—vagina—acquired immunodeficiency syndrome	0.000252	0.00304	CbGeAlD
Olanzapine—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000251	0.00303	CbGeAlD
Olanzapine—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000248	0.00298	CbGeAlD
Olanzapine—ORM1—lymph node—acquired immunodeficiency syndrome	0.000245	0.00296	CbGeAlD
Olanzapine—DRD2—lung—acquired immunodeficiency syndrome	0.000245	0.00295	CbGeAlD
Olanzapine—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000243	0.00293	CbGeAlD
Olanzapine—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000242	0.00292	CbGeAlD
Olanzapine—HTR7—nervous system—acquired immunodeficiency syndrome	0.00024	0.00289	CbGeAlD
Olanzapine—ADRA2C—lung—acquired immunodeficiency syndrome	0.000238	0.00287	CbGeAlD
Olanzapine—HTR1B—brain—acquired immunodeficiency syndrome	0.000238	0.00287	CbGeAlD
Olanzapine—CHRM2—brain—acquired immunodeficiency syndrome	0.000237	0.00285	CbGeAlD
Olanzapine—CYP1A2—blood—acquired immunodeficiency syndrome	0.000236	0.00284	CbGeAlD
Olanzapine—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000235	0.00283	CbGeAlD
Olanzapine—HRH1—digestive system—acquired immunodeficiency syndrome	0.000232	0.00279	CbGeAlD
Olanzapine—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.000232	0.00279	CbGeAlD
Olanzapine—HTR7—central nervous system—acquired immunodeficiency syndrome	0.000231	0.00279	CbGeAlD
Olanzapine—HTR1D—brain—acquired immunodeficiency syndrome	0.000231	0.00278	CbGeAlD
Olanzapine—HTR2C—brain—acquired immunodeficiency syndrome	0.000228	0.00275	CbGeAlD
Olanzapine—DRD2—nervous system—acquired immunodeficiency syndrome	0.000227	0.00274	CbGeAlD
Olanzapine—CYP2C9—blood—acquired immunodeficiency syndrome	0.000224	0.0027	CbGeAlD
Olanzapine—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.000223	0.00269	CbGeAlD
Olanzapine—ALB—brain—acquired immunodeficiency syndrome	0.000223	0.00268	CbGeAlD
Olanzapine—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000221	0.00266	CbGeAlD
Olanzapine—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000219	0.00263	CbGeAlD
Olanzapine—ADRA2A—blood—acquired immunodeficiency syndrome	0.000217	0.00261	CbGeAlD
Olanzapine—CHRM1—brain—acquired immunodeficiency syndrome	0.000216	0.0026	CbGeAlD
Olanzapine—ALB—lymph node—acquired immunodeficiency syndrome	0.000215	0.00259	CbGeAlD
Olanzapine—HTR2B—brain—acquired immunodeficiency syndrome	0.000214	0.00258	CbGeAlD
Olanzapine—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000213	0.00256	CbGeAlD
Olanzapine—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000209	0.00252	CbGeAlD
Olanzapine—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000207	0.0025	CbGeAlD
Olanzapine—CYP1A2—lung—acquired immunodeficiency syndrome	0.000207	0.00249	CbGeAlD
Olanzapine—HRH1—vagina—acquired immunodeficiency syndrome	0.000205	0.00247	CbGeAlD
Olanzapine—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000201	0.00242	CbGeAlD
Olanzapine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000194	0.00233	CbGeAlD
Olanzapine—HRH1—lung—acquired immunodeficiency syndrome	0.000194	0.00233	CbGeAlD
Olanzapine—CHRM3—brain—acquired immunodeficiency syndrome	0.000193	0.00232	CbGeAlD
Olanzapine—HTR1A—brain—acquired immunodeficiency syndrome	0.000192	0.00231	CbGeAlD
Olanzapine—ADRA2A—lung—acquired immunodeficiency syndrome	0.00019	0.00229	CbGeAlD
Olanzapine—HTR2A—blood—acquired immunodeficiency syndrome	0.000185	0.00222	CbGeAlD
Olanzapine—HTR7—brain—acquired immunodeficiency syndrome	0.000184	0.00221	CbGeAlD
Olanzapine—ABCB1—retina—acquired immunodeficiency syndrome	0.000181	0.00218	CbGeAlD
Olanzapine—HRH1—nervous system—acquired immunodeficiency syndrome	0.000179	0.00216	CbGeAlD
Olanzapine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000179	0.00216	CbGeAlD
Olanzapine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000178	0.00214	CbGeAlD
Olanzapine—ADRA1A—brain—acquired immunodeficiency syndrome	0.000177	0.00213	CbGeAlD
Olanzapine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000176	0.00213	CbGeAlD
Olanzapine—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000176	0.00212	CbGeAlD
Olanzapine—DRD2—brain—acquired immunodeficiency syndrome	0.000174	0.00209	CbGeAlD
Olanzapine—HRH1—central nervous system—acquired immunodeficiency syndrome	0.000173	0.00208	CbGeAlD
Olanzapine—HTR2A—vagina—acquired immunodeficiency syndrome	0.000171	0.00206	CbGeAlD
Olanzapine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000171	0.00206	CbGeAlD
Olanzapine—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.00017	0.00204	CbGeAlD
Olanzapine—ADRA2C—brain—acquired immunodeficiency syndrome	0.000169	0.00203	CbGeAlD
Olanzapine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000168	0.00203	CbGeAlD
Olanzapine—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000163	0.00196	CbGeAlD
Olanzapine—HTR2A—lung—acquired immunodeficiency syndrome	0.000162	0.00195	CbGeAlD
Olanzapine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.00015	0.0018	CbGeAlD
Olanzapine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000144	0.00174	CbGeAlD
Olanzapine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000139	0.00167	CbGeAlD
Olanzapine—HRH1—brain—acquired immunodeficiency syndrome	0.000137	0.00165	CbGeAlD
Olanzapine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000136	0.00164	CbGeAlD
Olanzapine—ADRA2A—brain—acquired immunodeficiency syndrome	0.000135	0.00162	CbGeAlD
Olanzapine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000134	0.00161	CbGeAlD
Olanzapine—HRH1—lymph node—acquired immunodeficiency syndrome	0.000132	0.0016	CbGeAlD
Olanzapine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000131	0.00158	CbGeAlD
Olanzapine—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.00013	0.00157	CbGeAlD
Olanzapine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000129	0.00155	CbGeAlD
Olanzapine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000127	0.00153	CbGeAlD
Olanzapine—ABCB1—blood—acquired immunodeficiency syndrome	0.000121	0.00146	CbGeAlD
Olanzapine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000117	0.00141	CbGeAlD
Olanzapine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000117	0.0014	CbGeAlD
Olanzapine—HTR2A—brain—acquired immunodeficiency syndrome	0.000115	0.00138	CbGeAlD
Olanzapine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000112	0.00135	CbGeAlD
Olanzapine—ABCB1—lung—acquired immunodeficiency syndrome	0.000106	0.00128	CbGeAlD
Olanzapine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000104	0.00126	CbGeAlD
Olanzapine—ABCB1—nervous system—acquired immunodeficiency syndrome	9.82e-05	0.00118	CbGeAlD
Olanzapine—ABCB1—central nervous system—acquired immunodeficiency syndrome	9.45e-05	0.00114	CbGeAlD
Olanzapine—ABCB1—brain—acquired immunodeficiency syndrome	7.5e-05	0.000904	CbGeAlD
Olanzapine—ABCB1—lymph node—acquired immunodeficiency syndrome	7.25e-05	0.000874	CbGeAlD
Olanzapine—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.22e-05	0.000142	CbGpPWpGaD
Olanzapine—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.22e-05	0.000142	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.22e-05	0.000142	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.22e-05	0.000142	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.22e-05	0.000142	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.22e-05	0.000142	CbGpPWpGaD
Olanzapine—HTR6—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.22e-05	0.000142	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.21e-05	0.000142	CbGpPWpGaD
Olanzapine—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.21e-05	0.000142	CbGpPWpGaD
Olanzapine—HTR7—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000142	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.21e-05	0.000141	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.21e-05	0.000141	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.21e-05	0.000141	CbGpPWpGaD
Olanzapine—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.21e-05	0.000141	CbGpPWpGaD
Olanzapine—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000141	CbGpPWpGaD
Olanzapine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.2e-05	0.00014	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.2e-05	0.00014	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.2e-05	0.00014	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.2e-05	0.000139	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.18e-05	0.000138	CbGpPWpGaD
Olanzapine—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.18e-05	0.000138	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.18e-05	0.000138	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.18e-05	0.000137	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.18e-05	0.000137	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.16e-05	0.000136	CbGpPWpGaD
Olanzapine—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.16e-05	0.000135	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.16e-05	0.000135	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.16e-05	0.000135	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.16e-05	0.000135	CbGpPWpGaD
Olanzapine—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.15e-05	0.000134	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.14e-05	0.000133	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.14e-05	0.000133	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.13e-05	0.000132	CbGpPWpGaD
Olanzapine—HTR6—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.13e-05	0.000132	CbGpPWpGaD
Olanzapine—HTR7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.13e-05	0.000131	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.13e-05	0.000131	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.13e-05	0.000131	CbGpPWpGaD
Olanzapine—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.12e-05	0.000131	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.12e-05	0.000131	CbGpPWpGaD
Olanzapine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	1.12e-05	0.00013	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.12e-05	0.00013	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.11e-05	0.00013	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.11e-05	0.00013	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.11e-05	0.00013	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.11e-05	0.000129	CbGpPWpGaD
Olanzapine—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000129	CbGpPWpGaD
Olanzapine—HTR6—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000129	CbGpPWpGaD
Olanzapine—HTR7—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000129	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.1e-05	0.000128	CbGpPWpGaD
Olanzapine—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000128	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.1e-05	0.000128	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.1e-05	0.000128	CbGpPWpGaD
Olanzapine—HRH4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000128	CbGpPWpGaD
Olanzapine—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000128	CbGpPWpGaD
Olanzapine—HRH4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.09e-05	0.000127	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.08e-05	0.000126	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.08e-05	0.000126	CbGpPWpGaD
Olanzapine—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.07e-05	0.000125	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.07e-05	0.000125	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.07e-05	0.000125	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.06e-05	0.000124	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.06e-05	0.000124	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.06e-05	0.000124	CbGpPWpGaD
Olanzapine—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.06e-05	0.000123	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.05e-05	0.000123	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.05e-05	0.000123	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.05e-05	0.000122	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.05e-05	0.000122	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.05e-05	0.000122	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.05e-05	0.000122	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.05e-05	0.000122	CbGpPWpGaD
Olanzapine—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.05e-05	0.000122	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.04e-05	0.000122	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.04e-05	0.000122	CbGpPWpGaD
Olanzapine—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000121	CbGpPWpGaD
Olanzapine—HTR5A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000121	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.03e-05	0.000121	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.03e-05	0.000121	CbGpPWpGaD
Olanzapine—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.03e-05	0.00012	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.03e-05	0.00012	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.03e-05	0.00012	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.03e-05	0.00012	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.02e-05	0.000119	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.02e-05	0.000119	CbGpPWpGaD
Olanzapine—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.01e-05	0.000117	CbGpPWpGaD
Olanzapine—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.97e-06	0.000116	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.71e-06	0.000113	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.6e-06	0.000112	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.58e-06	0.000112	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.58e-06	0.000112	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.58e-06	0.000112	CbGpPWpGaD
Olanzapine—HTR1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.54e-06	0.000111	CbGpPWpGaD
Olanzapine—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.5e-06	0.000111	CbGpPWpGaD
Olanzapine—HTR1E—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.49e-06	0.000111	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.46e-06	0.00011	CbGpPWpGaD
Olanzapine—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.37e-06	0.000109	CbGpPWpGaD
Olanzapine—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.32e-06	0.000109	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.27e-06	0.000108	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.22e-06	0.000108	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.13e-06	0.000106	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.08e-06	0.000106	CbGpPWpGaD
Olanzapine—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.99e-06	0.000105	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.97e-06	0.000105	CbGpPWpGaD
Olanzapine—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.95e-06	0.000104	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.9e-06	0.000104	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.84e-06	0.000103	CbGpPWpGaD
Olanzapine—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	8.83e-06	0.000103	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.83e-06	0.000103	CbGpPWpGaD
Olanzapine—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.7e-06	0.000101	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.7e-06	0.000101	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.65e-06	0.000101	CbGpPWpGaD
Olanzapine—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.57e-06	9.99e-05	CbGpPWpGaD
Olanzapine—HRH2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.5e-06	9.91e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.46e-06	9.87e-05	CbGpPWpGaD
Olanzapine—HRH2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.46e-06	9.86e-05	CbGpPWpGaD
Olanzapine—DRD5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.44e-06	9.85e-05	CbGpPWpGaD
Olanzapine—DRD5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.4e-06	9.8e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.35e-06	9.74e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.31e-06	9.69e-05	CbGpPWpGaD
Olanzapine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.26e-06	9.63e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.17e-06	9.52e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.14e-06	9.49e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.13e-06	9.47e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.11e-06	9.46e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.08e-06	9.42e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.02e-06	9.35e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.01e-06	9.34e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.99e-06	9.32e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.96e-06	9.29e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.95e-06	9.27e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.94e-06	9.26e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.9e-06	9.22e-05	CbGpPWpGaD
Olanzapine—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.9e-06	9.21e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.89e-06	9.2e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.87e-06	9.18e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.86e-06	9.17e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.85e-06	9.15e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.84e-06	9.14e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.82e-06	9.12e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.78e-06	9.07e-05	CbGpPWpGaD
Olanzapine—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.77e-06	9.06e-05	CbGpPWpGaD
Olanzapine—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.75e-06	9.04e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.74e-06	9.03e-05	CbGpPWpGaD
Olanzapine—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.73e-06	9.01e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.72e-06	9.01e-05	CbGpPWpGaD
Olanzapine—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.7e-06	8.98e-05	CbGpPWpGaD
Olanzapine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.63e-06	8.9e-05	CbGpPWpGaD
Olanzapine—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.61e-06	8.87e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.33e-06	8.55e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.29e-06	8.49e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.21e-06	8.41e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.2e-06	8.39e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.18e-06	8.37e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.18e-06	8.37e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.17e-06	8.36e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.15e-06	8.34e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.08e-06	8.26e-05	CbGpPWpGaD
Olanzapine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.07e-06	8.24e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.06e-06	8.24e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.06e-06	8.23e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.04e-06	8.21e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.02e-06	8.18e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7e-06	8.16e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.93e-06	8.08e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.93e-06	8.08e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.91e-06	8.06e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	6.89e-06	8.03e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.56e-06	7.65e-05	CbGpPWpGaD
Olanzapine—HTR6—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.52e-06	7.6e-05	CbGpPWpGaD
Olanzapine—HTR7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.51e-06	7.59e-05	CbGpPWpGaD
Olanzapine—HTR6—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.49e-06	7.56e-05	CbGpPWpGaD
Olanzapine—HTR7—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.48e-06	7.55e-05	CbGpPWpGaD
Olanzapine—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.47e-06	7.54e-05	CbGpPWpGaD
Olanzapine—HRH4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.44e-06	7.51e-05	CbGpPWpGaD
Olanzapine—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.44e-06	7.5e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.42e-06	7.49e-05	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.33e-06	7.39e-05	CbGpPWpGaD
Olanzapine—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.3e-06	7.35e-05	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.23e-06	7.27e-05	CbGpPWpGaD
Olanzapine—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.2e-06	7.23e-05	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.15e-06	7.17e-05	CbGpPWpGaD
Olanzapine—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.12e-06	7.13e-05	CbGpPWpGaD
Olanzapine—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	6.1e-06	7.11e-05	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.95e-06	6.94e-05	CbGpPWpGaD
Olanzapine—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.92e-06	6.9e-05	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.89e-06	6.87e-05	CbGpPWpGaD
Olanzapine—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.86e-06	6.83e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.61e-06	6.54e-05	CbGpPWpGaD
Olanzapine—HTR1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.61e-06	6.54e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	5.59e-06	6.52e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.58e-06	6.51e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.54e-06	6.46e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.51e-06	6.42e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5e-06	5.83e-05	CbGpPWpGaD
Olanzapine—HRH2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5e-06	5.82e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.97e-06	5.8e-05	CbGpPWpGaD
Olanzapine—DRD5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.96e-06	5.79e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.83e-06	5.63e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.8e-06	5.6e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.8e-06	5.6e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.78e-06	5.57e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.67e-06	5.44e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.65e-06	5.42e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.6e-06	5.36e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.57e-06	5.33e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.24e-06	4.94e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.22e-06	4.91e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.17e-06	4.86e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.16e-06	4.85e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.15e-06	4.84e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.15e-06	4.83e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.14e-06	4.83e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.13e-06	4.82e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.13e-06	4.81e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.11e-06	4.79e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.09e-06	4.77e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.08e-06	4.76e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.07e-06	4.75e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.06e-06	4.74e-05	CbGpPWpGaD
Olanzapine—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	3.96e-06	4.62e-05	CbGpPWpGaD
Olanzapine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	3.87e-06	4.51e-05	CbGpPWpGaD
Olanzapine—HTR6—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.83e-06	4.47e-05	CbGpPWpGaD
Olanzapine—HTR7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.83e-06	4.46e-05	CbGpPWpGaD
Olanzapine—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.8e-06	4.43e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.79e-06	4.42e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.77e-06	4.4e-05	CbGpPWpGaD
Olanzapine—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.72e-06	4.34e-05	CbGpPWpGaD
Olanzapine—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.66e-06	4.27e-05	CbGpPWpGaD
Olanzapine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	3.64e-06	4.25e-05	CbGpPWpGaD
Olanzapine—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.61e-06	4.21e-05	CbGpPWpGaD
Olanzapine—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	3.61e-06	4.21e-05	CbGpPWpGaD
Olanzapine—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.5e-06	4.08e-05	CbGpPWpGaD
Olanzapine—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.46e-06	4.04e-05	CbGpPWpGaD
Olanzapine—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.3e-06	3.85e-05	CbGpPWpGaD
Olanzapine—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.25e-06	3.79e-05	CbGpPWpGaD
Olanzapine—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.09e-06	3.6e-05	CbGpPWpGaD
Olanzapine—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.94e-06	3.43e-05	CbGpPWpGaD
Olanzapine—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.84e-06	3.31e-05	CbGpPWpGaD
Olanzapine—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.82e-06	3.29e-05	CbGpPWpGaD
Olanzapine—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.74e-06	3.2e-05	CbGpPWpGaD
Olanzapine—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.7e-06	3.15e-05	CbGpPWpGaD
Olanzapine—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.49e-06	2.9e-05	CbGpPWpGaD
Olanzapine—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.45e-06	2.86e-05	CbGpPWpGaD
Olanzapine—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.44e-06	2.85e-05	CbGpPWpGaD
Olanzapine—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.44e-06	2.84e-05	CbGpPWpGaD
Olanzapine—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.43e-06	2.83e-05	CbGpPWpGaD
Olanzapine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.41e-06	2.8e-05	CbGpPWpGaD
Olanzapine—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.4e-06	2.8e-05	CbGpPWpGaD
Olanzapine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.38e-06	2.78e-05	CbGpPWpGaD
Olanzapine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.23e-06	2.6e-05	CbGpPWpGaD
